Minoryx Therapeutics, CataloniaBio & HealthTech member, has created a fully owned subsidiary in Belgium. The new office, located in Brussels South Biopark (Charleroi) is due to launch operations this month.
The Belgian subsidiary will leverage the local biotech ecosystem to lead the research and development of MIN-102 in new orphan central nervous system (CNS) indications and will play an important role in the development of the company.
Minoryx is recruiting several R&D positions for its Belgian site and headquarters in Tecnocampus Maresme-Mataró (Barcelona).
The company recently completed a €21,3 million Series B funding round led by the Belgian Fund+ and joined by the public players SFPI-FPIM, SRIW and Sambrinvest.
Photo: Marc Martinell, co-founder and CEO of Minoryx - © Minoryx Therapeutics
Comments